Atherol	Vov	a Inc.
Form 8-	-K	
August	13,	2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report:
(Date of earliest event reported)
August 13, 2013
ATHERONOVA INC.
(Exact name of registrant as specified in charter)
Delaware

Edgar Filing: AtheroNova Inc. - Form 8-K

(State or other Jurisdiction of Incorporation or Organization)

000-52315		20-1915083		
(Commission File Number		(IRS Employer Identification No.)		
	2301 Dupont Drive, Suite 525			
	Irvine, CA 92612			
	(Address of Principal Executive Offices and zip code)			
(949) 476-1100				
(Registrant's telephone number, including area coo	de)			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:				
[] Written communication	ns pursuant to Rule 425 under the Securities Act (17 CF	R 230.425)		
[] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))				
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				

Item 8.01. Other Events.

On August 13, 2103, Thomas W. Gardner, the Registrant's Chief Executive Officer, commenced small group presentations regarding the Registrant. A copy of Mr. Gardner's presentation is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

The following exhibits are filed herewith:

Exhibit

Description

Number

99.1 AtheroNova Inc. Company Presentation.*

* Furnished, not filed.

2

Edgar Filing: AtheroNova Inc. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AtheroNova Inc.

Date: August 13, 2013 By: /s/ Mark Selawski

Mark Selawski

Chief Financial Officer & Secretary

3